871025-06-8 Usage
Uses
Used in Oncology:
Olaparib is used as an anticancer agent specifically for the treatment of ovarian and breast cancer. Its application is particularly beneficial for patients with specific genetic mutations, as it has been shown to improve progression-free survival and overall survival rates in clinical trials.
Used in Targeted Cancer Therapy:
As a targeted therapy, 6-(furan-2-yl)-5H-pyrrolo[3,2-d]pyrimidin-4-ol is used to inhibit the PARP enzyme, which plays a significant role in DNA repair mechanisms within cancer cells. By blocking this enzyme, the compound leads to the accumulation of DNA damage, ultimately inducing cell death and offering a precision approach to cancer treatment.
Used in Pharmaceutical Development:
Olaparib serves as a key compound in the development of pharmaceuticals for cancer treatment. Its success in clinical trials highlights the importance of targeted therapies in oncology and encourages further research into similar compounds that can be tailored to address specific genetic mutations and cancer types.
Check Digit Verification of cas no
The CAS Registry Mumber 871025-06-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,7,1,0,2 and 5 respectively; the second part has 2 digits, 0 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 871025-06:
(8*8)+(7*7)+(6*1)+(5*0)+(4*2)+(3*5)+(2*0)+(1*6)=148
148 % 10 = 8
So 871025-06-8 is a valid CAS Registry Number.
871025-06-8Relevant academic research and scientific papers
FUSED HETEROCYCLIC COMPOUND
-
Page/Page column 142, (2008/06/13)
The present invention relates to a compound represented by the formula: wherein W is C(R 1 ) or N, each A is an optionally substituted aryl group or a heteroaryl group, X 1 is -NR 3 -Y 1 -, -O-, -S-, -SO-, -SO 2 or -CHR 3 - wherein R 3 is a hydrogen atom or an optionally substituted aliphatic hydrocarbon group, or R 3 is optionally bonded to A to form an optionally substituted ring structure, R 1 is a hydrogen atom or an optionally substituted group bonded via a carbon atom, a nitrogen atom or an oxygen atom, R 2 is a hydrogen atom or optionally substituted group bonded via a carbon atom or a sulfur atom, or R 1 and R 2 , or R 2 and R 3 are optionally bonded to form an optionally substituted ring structure, or a salt thereof, and a tyrosine kinase inhibitor or an agent for the prophylaxis or treatment of cancer, which contains this compound or a prodrug thereof.
